# CORBUS PHARMACEUTICALS HLDGS (CRBP)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/CRBP/

- Reporting holders: 6
- Reported value: $527.4K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [DOLIVER ADVISORS, LP](https://holderbook.com/funds/938077-doliver-advisors-lp/) | $518.1K | 75,975 | 0.1% | 1 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $4.1K | 601 | 0.0% | 6 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $3.8K | 556 | 0.0% | 9 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $1.2K | 170 | 0.0% | 1 |
| [CoreCap Advisors, LLC](https://holderbook.com/funds/1902501-corecap-advisors-llc/) | $171 | 25 | 0.0% | 4 |
| [EASTERN BANK](https://holderbook.com/funds/1126395-eastern-bank/) | $41 | 6 | 0.0% | 7 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 6 | $527.4K |
| Q2 2026 | 112 | $158.4M |
| Q1 2026 | 107 | $125.6M |
| Q4 2025 | 101 | $108.9M |
| Q3 2025 | 87 | $117.4M |
| Q2 2025 | 82 | $62.9M |
| Q1 2025 | 86 | $55.6M |
| Q4 2024 | 100 | $136.6M |
| Q3 2024 | 113 | $285.0M |
| Q2 2024 | 108 | $489.0M |
| Q1 2024 | 83 | $357.0M |
| Q4 2023 | 33 | $4.8M |